…
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Axogen develops and commercializes surgical solutions for peripheral nerve repair, notably regenerative nerve grafts and protective soft-tissue products for traumatic and surgical nerve injuries. Long-term growth may be supported by wider clinical adoption, expanded indications, international expansion and rising procedure volumes from an aging population, and the company appears positioned as a focused specialist with surgeon training and product differentiation.
Key risks include reliance on a narrow procedure set with variable reimbursement, competition from autografts and alternative technologies, and execution and financial constraints that could impede growth.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -15.70M | -9.96M | -21.72M | -28.95M | -26.98M |
| Net income | -15.70M | -9.96M | -21.72M | -27.34M | -28.06M |
| Selling general administrative | 44.58M | 39.04M | 38.41M | 36.76M | 32.34M |
| Selling and marketing expenses | 97.74M | 78.46M | 77.58M | 80.23M | 73.33M |
| Gross profit | 167.35M | 141.98M | 121.87M | 114.44M | 104.43M |
| Reconciled depreciation | 8.51M | 7.84M | 4.87M | 4.85M | 4.74M |
| Ebit | -8.00M | -1.76M | -18.88M | -29.71M | -25.42M |
| Ebitda | 0.19M | 6.08M | -13.33M | -25.08M | -20.95M |
| Depreciation and amortization | 8.19M | 7.84M | 5.55M | 4.62M | 4.46M |
| Non operating income net other | - | - | - | 1.38M | -0.21M |
| Operating income | -7.85M | -3.29M | -21.46M | -29.71M | -25.42M |
| Other operating expenses | 233.06M | 190.62M | 180.47M | 168.29M | 152.77M |
| Interest expense | 7.70M | 8.21M | 2.83M | 0.62M | 1.36M |
| Net interest income | -7.70M | -8.21M | -0.95M | -0.62M | -1.36M |
| Income tax expense | - | - | 5.39M | -1.61M | 1.08M |
| Total revenue | 225.21M | 187.34M | 159.01M | 138.58M | 127.36M |
| Total operating expenses | 175.20M | 145.26M | 143.33M | 144.14M | 129.84M |
| Cost of revenue | 57.85M | 45.36M | 37.14M | 24.15M | 22.93M |
| Total other income expense net | -7.85M | -6.68M | -0.25M | 0.76M | -1.57M |
| Net income from continuing ops | -15.70M | -9.96M | -23.24M | -28.95M | -26.98M |
| Net income applicable to common shares | - | - | - | -28.95M | -26.98M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 221.69M | 203.73M | 196.83M | 195.39M | 208.02M |
| Intangible assets | 6.75M | 5.58M | 4.53M | 3.65M | 2.86M |
| Other current assets | 16.33M | 8.45M | 2.81M | 1.94M | 1.86M |
| Total liab | 92.84M | 99.82M | 101.16M | 94.39M | 95.47M |
| Total stockholder equity | 128.85M | 103.91M | 95.67M | 101.00M | 112.55M |
| Deferred long term liab | - | - | - | 4.52M | 5.56M |
| Other current liab | 21.18M | 20.63M | 17.11M | 13.48M | 16.54M |
| Common stock | 0.47M | 0.44M | 0.43M | 0.42M | 0.42M |
| Capital stock | 0.47M | 0.44M | 0.43M | 0.42M | 0.42M |
| Retained earnings | -306.96M | -291.26M | -281.30M | -259.58M | -230.63M |
| Cash | 35.55M | 27.55M | 37.03M | 15.28M | 32.76M |
| Total current liabilities | 23.56M | 30.61M | 30.43M | 23.75M | 24.29M |
| Net debt | -16.31M | 41.13M | 32.27M | 52.14M | 34.70M |
| Short term debt | 2.37M | 1.97M | 1.55M | 1.31M | 1.83M |
| Short long term debt total | 19.24M | 68.69M | 69.29M | 67.43M | 67.45M |
| Other stockholder equity | 435.34M | 394.73M | 376.53M | 360.15M | 342.76M |
| Property plant equipment | - | - | - | 93.66M | 78.12M |
| Total current assets | 120.42M | 99.22M | 88.00M | 98.08M | 127.05M |
| Net tangible assets | - | - | - | 97.35M | 109.69M |
| Short term investments | 5.98M | 5.93M | 0.00M | 33.51M | 51.33M |
| Net receivables | 26.17M | 24.11M | 25.15M | 22.19M | 18.16M |
| Long term debt | 48.39M | 47.50M | 46.60M | 66.12M | 65.62M |
| Inventory | 42.37M | 33.18M | 23.02M | 18.91M | 16.69M |
| Accounts payable | 2.89M | 8.01M | 11.77M | 8.96M | 5.92M |
| Accumulated other comprehensive income | - | - | 0.00M | - | - |
| Common stock total equity | - | - | - | 0.42M | 0.42M |
| Retained earnings total equity | - | - | - | -259.58M | -230.63M |
| Non currrent assets other | - | - | - | 93.66M | 0.04M |
| Non current assets total | 101.27M | 104.51M | 108.82M | 97.31M | 80.97M |
| Capital lease obligations | 19.24M | 21.19M | 22.69M | 21.71M | 22.63M |
| Long term debt total | - | - | - | 66.12M | 65.62M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | 0.28M | -10.30M | 18.32M | 18.05M | 3.80M |
| Change to liabilities | - | - | - | 0.66M | -0.27M |
| Total cashflows from investing activities | -5.32M | -10.30M | - | -3.20M | -23.65M |
| Net borrowings | -0.03M | -0.01M | - | -0.01M | 14.98M |
| Total cash from financing activities | 10.50M | 2.29M | 1.95M | 1.79M | 20.45M |
| Change to operating activities | - | - | - | -1.93M | 1.97M |
| Net income | -15.70M | -9.96M | -21.72M | -28.95M | -26.98M |
| Change in cash | 5.99M | -3.47M | 15.49M | -17.47M | -16.60M |
| Begin period cash flow | 33.55M | 37.03M | 21.54M | 39.01M | 55.61M |
| End period cash flow | 39.55M | 33.55M | 37.03M | 21.54M | 39.01M |
| Total cash from operating activities | 0.81M | 4.54M | -5.72M | -16.07M | -13.40M |
| Issuance of capital stock | - | - | - | 0.00M | 0.00M |
| Depreciation | 8.19M | 7.84M | 5.55M | 4.85M | 4.74M |
| Other cashflows from investing activities | -1.85M | -10.30M | - | -1.18M | 0.95M |
| Change to inventory | -9.19M | -10.16M | -6.05M | -3.66M | -7.48M |
| Change to account receivables | -2.46M | 0.39M | -2.69M | -4.64M | -0.50M |
| Sale purchase of stock | - | - | - | 1.81M | 5.47M |
| Other cashflows from financing activities | 10.50M | 2.30M | 1.96M | 1.81M | 5.47M |
| Change to netincome | - | - | - | 16.70M | 14.29M |
| Capital expenditures | 3.75M | 4.52M | 14.92M | 21.25M | 28.40M |
| Change receivables | - | - | - | -4.64M | -0.50M |
| Cash flows other operating | - | - | - | -0.17M | 3.79M |
| Cash and cash equivalents changes | - | - | - | -17.47M | -16.60M |
| Change in working capital | -24.62M | -10.04M | -4.39M | -9.56M | -6.28M |
| Stock based compensation | 30.11M | 15.91M | 14.42M | 15.59M | 10.92M |
| Other non cash items | 2.83M | 0.80M | 0.41M | 2.00M | 0.83M |
| Free cash flow | -2.93M | 0.01M | -20.63M | -37.32M | -41.80M |
Sector: Healthcare Industry: Medical Devices
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| AXGN Axogen Inc |
1.58 2.85% |
56.95 | - | 142.86 | 8.27 | 15.00 | 8.70 | 3862.43 |
| ABT Abbott Laboratories |
- -% |
104.48 | 25.97 | 17.24 | 3.57 | 3.20 | 3.81 | 16.75 |
| MDT Medtronic PLC |
-1.43 1.40% |
100.89 | 26.60 | 15.87 | 3.35 | 2.08 | 3.90 | 14.12 |
| SYK Stryker Corporation |
-3.48 1.09% |
314.67 | 29.23 | 16.86 | 4.18 | 4.51 | 4.63 | 17.16 |
| SEMHF Siemens Healthineers AG |
-0.10 0.22% |
47.50 | 39.57 | 21.32 | 3.01 | 3.29 | 2.95 | 16.92 |
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstructed nerve gaps. It also provides Axoguard HA+ Nerve Protector, a surgical implant for non-constricting protection of the peripheral nerves; Axoguard Nerve Cap, a porcine submucosa ECM product; Avive+ Soft Tissue Matrix, a multi-layer amniotic membrane allograft; and Avance Method, a technique to process Avance Nerve Graft from donated human peripheral nerve tissue. In addition, the company offers peripheral nerve tissue recovery and acquisition, and testing, as well as donor medical review and release, debridement and other processing steps, packaging, and sterilization. It provides its products to hospitals, surgery centers and military hospitals, calling on surgeons, including plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and certain oral and maxillofacial surgeons through independent in-country distributors. The company is headquartered in Alachua, Florida.
13631 Progress Boulevard, Alachua, FL, United States, 32615
386 462 6800
622
| Name | Title | Year Born |
|---|---|---|
| Ms. Karen Zaderej | Chairman, Pres & CEO | 1962 |
| Mr. Peter J. Mariani | Exec. VP & CFO | 1964 |
| Ms. Maria D. Martinez | Chief HR Officer | 1968 |
| Mr. Angelo G. Scopelianos Ph.D. | Chief R&D Officer | 1955 |
| Mr. Michael Donovan | VP of Operations | 1965 |
| Ed Joyce | Director of Investor Relations | NA |
| Mr. Bradley L. Ottinger J.D. | Gen. Counsel & Chief Compliance Officer | 1970 |
| Mr. Gregory Davault | VP of Marketing | 1968 |
| Ms. Doris Quackenbush | VP of Sales | NA |
| Ms. Isabelle Billet | Chief Strategy & Bus. Devel. Officer | 1962 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.